167 related articles for article (PubMed ID: 26692336)
1. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
Cameron RL; Kavanagh K; Pan J; Love J; Cuschieri K; Robertson C; Ahmed S; Palmer T; Pollock KG
Emerg Infect Dis; 2016 Jan; 22(1):56-64. PubMed ID: 26692336
[TBL] [Abstract][Full Text] [Related]
2. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen M; Luostarinen T; Vänskä S; Söderlund-Strand A; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Nieminen P; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Nov; 143(9):2299-2310. PubMed ID: 29845626
[TBL] [Abstract][Full Text] [Related]
3. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
[TBL] [Abstract][Full Text] [Related]
4. Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.
Baussano I; Lazzarato F; Ronco G; Lehtinen M; Dillner J; Franceschi S
J Infect Dis; 2017 Aug; 216(3):336-344. PubMed ID: 28859431
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
[TBL] [Abstract][Full Text] [Related]
6. Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview.
Kim MA; Han GH; Kim JH; Seo K
J Korean Med Sci; 2018 Dec; 33(52):e331. PubMed ID: 30584412
[TBL] [Abstract][Full Text] [Related]
7. Overcoming barriers in HPV vaccination and screening programs.
Vorsters A; Arbyn M; Baay M; Bosch X; de Sanjosé S; Hanley S; Karafillakis E; Lopalco PL; Pollock KG; Yarwood J; Van Damme P
Papillomavirus Res; 2017 Dec; 4():45-53. PubMed ID: 29179869
[TBL] [Abstract][Full Text] [Related]
8. Contemplating the Human Papillomavirus (HPV) Vaccine Introduction in Pakistan: Is Now the Time?
Batool R
Am J Trop Med Hyg; 2024 Apr; 110(4):631-632. PubMed ID: 38471175
[TBL] [Abstract][Full Text] [Related]
9. A Protocol for the secure linking of registries for HPV surveillance.
El Emam K; Samet S; Hu J; Peyton L; Earle C; Jayaraman GC; Wong T; Kantarcioglu M; Dankar F; Essex A
PLoS One; 2012; 7(7):e39915. PubMed ID: 22768321
[TBL] [Abstract][Full Text] [Related]
10. HPV vaccination programme success in Scotland.
Burki T
Lancet Oncol; 2024 Mar; 25(3):281. PubMed ID: 38310913
[No Abstract] [Full Text] [Related]
11. Creating immunity.
Fletcher S
CMAJ; 2003 Aug; 169(4):282-3; author reply 283. PubMed ID: 12925417
[No Abstract] [Full Text] [Related]
12. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
Van Damme P; Bonanni P; Bosch FX; Joura E; Kjaer SK; Meijer CJ; Petry KU; Soubeyrand B; Verstraeten T; Stanley M
Vaccine; 2016 Feb; 34(6):757-61. PubMed ID: 26772631
[TBL] [Abstract][Full Text] [Related]
13. [One decade of HPV vaccination in Germany].
Schneede P
Urologe A; 2017 Jun; 56(6):728-733. PubMed ID: 28455577
[TBL] [Abstract][Full Text] [Related]
14. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.
Mesher D; Panwar K; Thomas SL; Beddows S; Soldan K
BMJ Open; 2016 Feb; 6(2):e009915. PubMed ID: 26868944
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV): making the case for 'Immunisation for All'.
Prue G; Lawler M; Baker P; Warnakulasuriya S
Oral Dis; 2017 Sep; 23(6):726-730. PubMed ID: 27492979
[TBL] [Abstract][Full Text] [Related]
16. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.
Durham DP; Ndeffo-Mbah ML; Skrip LA; Jones FK; Bauch CT; Galvani AP
Proc Natl Acad Sci U S A; 2016 May; 113(18):5107-12. PubMed ID: 27091978
[TBL] [Abstract][Full Text] [Related]
17. Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.
Naber SK; Matthijsse SM; Rozemeijer K; Penning C; de Kok IM; van Ballegooijen M
PLoS One; 2016; 11(1):e0145548. PubMed ID: 26824771
[TBL] [Abstract][Full Text] [Related]
18. HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data.
Palmer TJ; McFadden M; Pollock KG; Kavanagh K; Cuschieri K; Cruickshank M; Nicoll S; Robertson C
Br J Cancer; 2016 Mar; 114(5):576-81. PubMed ID: 26794278
[TBL] [Abstract][Full Text] [Related]
19. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.
Lowy DR
J Clin Invest; 2016 Jan; 126(1):5-11. PubMed ID: 26727228
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of effects of HPV vaccination in Belgium.
Arbyn M; Broeck DV; Benoy I; Bogers J; Depuydt C; Praet M; Sutter PD; Hoorens A; Hauben E; Poppe W; Van Ranst M; Delvenne P; Gofflot S; Pétein M; Engelen F; Vanneste A; Beeck LO; Damme PV; Temmerman M; Weyers S
Cancer Epidemiol; 2016 Apr; 41():152-8. PubMed ID: 26895623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
